HOME >> MEDICINE >> NEWS
Panel offers guidelines on skin reactions to new class of cancer drugs

DURHAM, N.C., May 22 -- Skin reactions to a powerful new class of anti-cancer drugs are frequent, but manageable through a simple and rational treatment approach usually without the need to reduce the dose or interrupt treatment with potentially life-prolonging chemotherapy, according to an article in the May issue of "The Oncologist."

The special article presents the first recommendations on skin reactions to the new drugs, called Epidermal Growth Factor Receptor Inhibitors (EGFRIs). The guidelines were developed at an international multidisciplinary meeting, including medical oncologists, dermatologists, nurses, and pharmacists. "One important goal is to ensure that healthcare professionals and patients see EGFRI-associated dermatologic toxicity as manageable, thereby optimizing clinical benefit from continued and uninterrupted use of EGFRIs when possible," according to lead author Dr. Thomas J. Lynch, Jr., of Massachusetts General Hospital, Boston.

Treatment with EGFRIs has been shown to improve survival in patients with several types of cancer, including lung, pancreatic, and colorectal cancers. The drugs including erlotinib (Tarceva), cetuximab (Erbitux), and panitumumab (Vectibix) work by interfering with cell-signaling abnormalities that contribute to cancer development and growth.

Unfortunately, the EGFRIs carry a substantial risk of skin reactions more than half of treated patients have some type of skin toxicity, most commonly an acne-like rash. The reactions most likely occur because the receptor blocked by the drugs also performs key functions in normal skin. There is even evidence that the rash may be a sign that EGFRI anti-cancer treatment is working in some studies, patients with more severe skin reactions had better survival. The skin reactions are rarely so severe that the dosage is reduced or treatment stopped. Until recently, there was no strong scientific data to guide the treatment of skin reactions to EGFRIs
'"/>

Contact: George Kendall
gkendall@alphamedpress.com
919-680-0011
AlphaMed Press, Inc.
23-May-2007


Page: 1 2 3

Related medicine news :

1. Panel offers expert analysis on causes, prevention of stent thrombosis
2. Panel presents Agricultural Biosecurity & Sustainability Strategies at 2007 AAAS Meeting
3. Panel updates guidelines for treatment of adult HIV infection
4. Panel finds insufficient evidence to recommend for or against maternal-request Caesarean delivery
5. Panel calls for a new look at treatments commonly used for chronic insomnia
6. Hormone therapy offers new hope for ovarian cancer patients
7. TB test offers patients quicker and easier diagnosis
8. Supersize me mice research offers grim warning for Americas fast food consumers
9. New treatment offers relief from chronic back pain
10. Commonly used drug offers promise for premature babies
11. Stenting of abdominal arteries offers welcome relief for intestinal angina

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/21/2019)... ... August 21, 2019 , ... ... location in Huntsville, Ala. in early 2020. Alsana will offer an eating disorder ... Intensive Outpatient Program (IOP). The integrative program will provide a continuum of care ...
(Date:8/21/2019)... ... August 21, 2019 , ... Photoprotective Technologies (PPT) has just received US ... is currently used in skincare products such as creams or makeup and is distributed ... growing need to protect the skin from blue light as well as UV. ...
(Date:8/21/2019)... ... August 21, 2019 , ... ... technology: HDRX imaging. HDRX captures extremely high-resolution images of products for superior ... high image resolution at normal production line speeds within power settings used ...
(Date:8/19/2019)... ... August 19, 2019 , ... ... secondary packaging needs, announced the availability of resealable single-dose vials for a multitude ... the Guala Group, consists of five resealable breakaway vials and are available in ...
(Date:8/19/2019)... (PRWEB) , ... August 19, 2019 , ... ... than 12.5 million medically necessary and cosmetic procedures in 2018 – 7.5 percent ... its seventh year, the 2018 ASDS Survey on Dermatologic Procedures revealed ...
Breaking Medicine News(10 mins):
(Date:8/16/2019)... ... August 16, 2019 , ... Quantum Genomics ... potentially treat treatment-resistant hypertension by acting in the brain to interfere with the ... worldwide that are affected by treatment-resistant hypertension, resulting in almost 10 million deaths ...
(Date:8/16/2019)... (PRWEB) , ... August 16, 2019 , ... ... 1014 on its annual Inc. 5000 list, the most prestigious ranking of the ... successful companies within the American economy’s most dynamic segment—its independent small businesses. Microsoft, ...
(Date:8/15/2019)... ... August 15, 2019 , ... Men’s Health Memorial will celebrate the ... experts and learn how to regain their strength and vitality. , “While many ... step to do something about it is not always easy,” said Robert A. Ochoa, ...
Breaking Medicine Technology:
Cached News: